3 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | — | -$161M | — | — | -69.4% | -54.9% | -$154M | $25M | $124M |
| 2024 | — | -$127M | — | — | -47.8% | -41.8% | -$116M | — | $97M |
| 2023 | — | -$60M | — | — | 459.4% | -80.3% | -$53M | — | $35M |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | — | -$38M | — | — | -23.1% | -17.4% | — | $25M | $32M |
| Mar '26 | — | -$40M | — | — | -20.3% | -15.5% | — | — | $32M |
| Dec '25 | — | -$38M | — | — | -16.3% | -12.9% | -$34M | $25M | $124M |
| Sep '25 | — | -$37M | — | — | -24.2% | -19.7% | -$43M | — | $34M |
| Jun '25 | — | -$42M | — | — | -22.8% | -18.6% | -$32M | — | $53M |
| Mar '25 | — | -$45M | — | — | -19.9% | -17.1% | -$45M | — | $57M |
| Dec '24 | — | -$37M | — | — | -14.1% | -12.3% | -$38M | — | $97M |
| Sep '24 | — | -$34M | — | — | -11.4% | -10.2% | -$28M | — | $105M |
| Jun '24 | — | -$29M | — | — | -8.6% | -7.9% | -$25M | — | $132M |
| Mar '24 | — | -$27M | — | — | -7.4% | -6.8% | -$26M | — | $224M |
| Dec '23 | — | -$21M | — | — | 157.3% | -27.5% | -$19M | — | $35M |
| Sep '23 | — | -$15M | — | — | 13.8% | — | -$11M | — | $23M |
| Jun '23 | — | -$13M | — | — | 13.5% | — | -$11M | — | $53M |
| Mar '23 | — | -$11M | — | — | 13.2% | — | -$11M | — | $40M |
See the revenue and net-income charts above for Kyverna Therapeutics, Inc.'s multi-year trend.
As of FY2025, Kyverna Therapeutics, Inc. reported $25M of total debt against $124M of cash; operating income covered interest expense -347.3×.
In FY2025, gross margin was —, operating margin —, and net margin —.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.